Patent details
LUC50011
Product Name:
Atezolizumab
Basic Information
- Publication number:
- LUC50011
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP232146878
- Legal Status:
- Pending & Published
- Application number:
- LUC50011
- First applicant's nationality:
- Procedural language:
- French
Paediatric Extension
- SPC Extension Filing Date:
- 10/06/2025
- SPC Extension Agent Name:
-
OFFICE FREYLINGER S.A.
- SPC Extension Status:
- Pending & Published
- SPC Extension Grant Date:
-
- SPC Extension Rejection Date:
-
Marketing Authorization
- Marketing Authorization Number:
- EU/1/17/1220
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 25/09/2017
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 06/06/2025
- First Marketing Authorization date:
- 25/09/2017
- Grant date:
- Activation date:
- Publication date:
- 06/06/2025
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 25/09/2032
- SPC Extension Expiration:
- 25/03/2033
- Rejection date:
- Withdrawal date:
Owner
- From:
- 06/06/2025
-
-
- Name:
- F. Hoffmann-La Roche AG
- Address:
- Grenzacherstrasse 124, 4070 Basel, Switzerland (CH)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 06/06/2025
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2025/08
- Publication date:
- 03/07/2025
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPCX1
- Bulletin edition number:
- 2025/08
- Publication date:
- 03/07/2025
- Description:
- Section G : Applications for extensions for pediatric use – I1E publication
Annual Fees
- Annual Fee Due Date:
- 31/12/2029
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-